Melanoma is the most serious of all cutaneous cancers.
In the case of late diagnosis, the prognosis is very poor, which is why early screening is essential.
Every year, 130,000 people throughout the world are diagnosed and over 37,000 deaths a year recorded.
It is the second most common cancer in young adults between 15 and 34 years of age.
In Caucasian populations worldwide, the incidence rate for melanoma doubles every 10 to 20 years.
MELAPRED enables you to determine your personal risk of melanoma and to make appropriate behavioural changes such as avoiding overexposure to the sun.
MELAPRED provides a doctor with the means to know a patient’s melanoma risk score and to follow up appropriately with a personalized approach, such as prevention advice and frequency of dermatological consultations.
MELAPRED is effective:
- developed by Genepredict in collaboration with teams from the Assistance Publique (French public health organization) and INSERM (French National Institute of Health and Medical Research).
- validated on many thousands of patients in different countries.
Recommendations in 2013 by the French National Authority for Health (Haute Autorité de Santé)
Early detection of melanoma offers the best chances of recovery.
It is crucial to identify the populations at risk and to place them under dermatological surveillance.
In this respect general practitioners have an important role to play.
Strategies for the prevention of melanoma must be developed in order to curb risk behaviours.
Screening effectiveness must be improved.